3 Top Growth Stocks to Buy in the Second Half of 2025
Key Takeaways
From an analytical perspective, What stands out here is For decades, Jim McKay introduced ABC's Wide World of Sports with a memorable phrase, "The thrill of victory, and the agony...
Article Overview
Quick insights and key information
5 min read
Estimated completion
investment
Article classification
July 19, 2025
05:45 AM
The Motley Fool
Original publisher
From an analytical perspective, What stands out here is For decades, Jim McKay introduced ABC's Wide World of Sports with a memorable phrase, "The thrill of victory, and the agony of defeat
On the other hand, " McKay's words could apply to many investors in the first half of this year (something worth watching)
There have been periods of victory -- and periods of defeat, given current economic conditions
Of course, the level of victory and defeat investors experienced dep on which stocks they owned (an important development), in light of current trends
If you want greater chances of winning going forward, the stocks you pick will make a huge difference
Which stocks should you consider
Here are three top growth stocks to buy in the second half of 2025
Moreover, Image source: Getty Images
Conversely, Alibaba Group Holding Wall Street loves Alibaba Group Holding (BABA -0, in today's market environment
On the other hand, Of the 40 analysts surveyed by LSEG in July, 37 rated the stock as a "buy" or a "strong buy (an important development). " The three outliers holding Alibaba
The consensus 12-month price target reflects an upside potential of roughly 40%
Nevertheless, I'm not always on the same page as Wall Street analysts, but I agree with the upbeat views Alibaba (something worth watching), in today's financial world
Nevertheless, For one thing, you can't even spell Alibaba without A and I. "Lbaba" just doesn't have the same ring to it
On the other hand, Alibaba is an artificial intelligence (AI) juggernaut in China
Its Alibaba Cloud unit commands 36% of the Chinese cloud infrastructure market, almost twice the market of its nearest rival, in light of current trends
Nevertheless, Additionally, Revenue from Alibaba Cloud's AI-related ducts has grown by triple-digit percentages for seven consecutive quarters (something worth watching)
The company also operates China's leading e-commerce platform
Alibaba's Taobao and Tmall online shopping sites continue to der solid revenue growth, and AI is helping imve the user experience on the platforms
But the main reason I Alibaba is its valuation
However, The stock trades at a forward earnings multiple of only 10
That's dirt cheap for a giant that raked in $137, in today's financial world. 3 billion in revenue and $17, in light of current trends
Moreover, 4 billion in fits in its last fiscal year
Meta Platforms Meta Platforms (META -0 (this bears monitoring), in light of current trends. 26%) could be an underappreciated leader in AI
Moreover, The analysis reveals 's not a pure-play AI company OpenAI
Meanwhile, It's not a cloud titan Amazon (NASDAQ: AMZN), Microsoft (NASDAQ: MSFT), and Alphabet's (NASDAQ: GOOG) (NASDAQ: GOOGL) Google
However, Meta is making a huge bet on AI that I suspect will pay off handsomely
Additionally, That wager is already paying off in some ways, in light of current trends
For example, AI is helping Meta imve its recommendation models
However, The company has seen a 5% higher conversion rate on Reels in the quarter
Conversely, Over the last six months, Meta's recommendation system imvements have led to a 7% increase in user time spent on Facebook and 6% on Instagram
More time on these social media apps translates to higher advertising revenue for Meta, considering recent developments
AI-powered messaging presents a tremendous growth opportunity for the company
Es in nations such as Thailand and Vietnam use Meta's messaging apps heavily to communicate with customers (an important development)
Meanwhile, With AI, this model could be deployed in the U, in today's financial world
However, Perhaps the most intriguing arena for Meta, though, is in AI devices
Market analysis shows company is already a leader in smart glasses thanks to its Ray-Ban Meta AI glasses
Its Quest virtual reality headsets remain highly with users
Nevertheless, I think Meta could be one of the biggest players in a potentially massive AI device market over the next few years (this bears monitoring)
Conversely, Vertex Pharmaceuticals Not every great growth stock that I recommend buying in the second half of 2025 is focused heavily on AI
Nevertheless, Vertex Pharmaceuticals (VRTX -0, considering recent developments
Additionally, 57%) is a drugmaker with terrific growth spects
So far in Vertex's history, cystic fibrosis (CF) has been the company's primary focus
That's worked out quite well for the big bio innovator
Moreover, In contrast, Vertex the only therapies that treat the underlying cause of CF
Meanwhile, Its CF drug, Alyftrek, offers the most convenient dosing in its lineup and will almost certainly become a blockbuster quickly
However, Vertex has expanded its horizons to other therapeutic areas (something worth watching)
On the other hand, Casgevy, the first apved CRISPR gene-editing therapy, targets two rare blood disorders -- sickle cell disease and transfusion-dependent beta-thalassemia
Earlier this year, Journavx became the first new class of pain medication apved by the U
Food and Drug Administration in more than two decades
Additionally, As a powerful pain drug that isn't an opioid, I expect this new duct will become another huge winner for Vertex (quite telling)
And there are potentially more big winners on the way
However, Vertex's pipeline features three other drugs in late-stage clinical testing, given the current landscape
Inaxaplin targets APOL1-mediated kidney disease
Additionally, Povetacicept's first targeted indication is chronic kidney disease IgA nephropathy
Zimislicel holds the potential to cure severe type 1 diabetes
I the chances of success for all three grams.
Related Articles
More insights from FinancialBooklet